Holen Sie sich die Stockscreener-App
41.45
2.17%
0.88
Vorhandelsmarkt:
41.25
-0.20
-0.48%
Schlusskurs vom Vortag:
$40.57
Offen:
$40.52
24-Stunden-Volumen:
2.73M
Relative Volume:
1.06
Marktkapitalisierung:
$8.55B
Einnahmen:
$2.10B
Nettoeinkommen (Verlust:
$402.17M
KGV:
21.41
EPS:
1.9357
Netto-Cashflow:
$403.87M
1W Leistung:
-0.14%
1M Leistung:
+11.42%
6M Leistung:
-25.48%
1J Leistung:
-17.76%
1-Tages-Spanne:
$40.51
$41.66
1-Wochen-Bereich:
$39.36
$41.78
52-Wochen-Spanne:
$32.53
$57.81
Qiagen Nv Stock (QGEN) Company Profile
Firmenname
Qiagen Nv
Sektor
Branche
Telefon
-
Adresse
-
Compare QGEN vs TMO, DHR, IDXX, A, NTRA
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
QGEN
Qiagen Nv
|
41.45 | 8.55B | 2.10B | 402.17M | 403.87M | 1.9357 |
TMO
Thermo Fisher Scientific Inc
|
572.32 | 212.69B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
192.50 | 135.32B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
539.37 | 42.55B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
139.74 | 39.47B | 7.23B | 1.41B | 1.09B | 4.979 |
NTRA
Natera Inc
|
264.69 | 37.91B | 2.50B | -226.32M | 71.51M | -1.6412 |
Qiagen Nv Stock (QGEN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-14 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2026-03-13 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2026-01-22 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2025-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-06-24 | Eingeleitet | Barclays | Overweight |
| 2025-04-04 | Herabstufung | Redburn Atlantic | Buy → Neutral |
| 2025-02-19 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2025-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-12-10 | Hochstufung | Jefferies | Hold → Buy |
| 2024-10-17 | Herabstufung | HSBC Securities | Buy → Hold |
| 2024-06-27 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2023-12-19 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-12-13 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-12-07 | Hochstufung | Goldman | Neutral → Buy |
| 2023-09-12 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-05-23 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-10-18 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-01-18 | Hochstufung | DZ Bank | Hold → Buy |
| 2021-10-15 | Fortgesetzt | Cowen | Market Perform |
| 2021-10-14 | Eingeleitet | Redburn | Buy |
| 2021-07-14 | Herabstufung | Kepler | Buy → Hold |
| 2021-06-03 | Eingeleitet | Goldman | Neutral |
| 2020-10-06 | Fortgesetzt | BofA Securities | Buy |
| 2020-09-28 | Hochstufung | Kepler | Hold → Buy |
| 2020-08-24 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-08-20 | Fortgesetzt | JP Morgan | Overweight |
| 2020-08-17 | Hochstufung | Berenberg | Hold → Buy |
| 2020-08-14 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2020-08-14 | Hochstufung | Exane BNP Paribas | Neutral → Outperform |
| 2020-03-04 | Herabstufung | Berenberg | Buy → Hold |
| 2020-01-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-01-07 | Eingeleitet | Citigroup | Neutral |
| 2019-12-26 | Fortgesetzt | BofA/Merrill | Underperform |
| 2019-11-15 | Eingeleitet | Stifel | Hold |
| 2019-11-14 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-11-14 | Hochstufung | JP Morgan | Underweight → Overweight |
| 2019-11-14 | Hochstufung | Kepler | Reduce → Hold |
| 2019-10-17 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2019-10-09 | Herabstufung | Kepler | Hold → Reduce |
| 2019-10-08 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2019-10-08 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2019-10-08 | Herabstufung | JP Morgan | Neutral → Underweight |
Alle ansehen
Qiagen Nv Aktie (QGEN) Neueste Nachrichten
Qiagen stock trades steadily as molecular diagnostics growth supports margins - Ad-hoc-news.de
Qiagen N.V. $QGEN Shares Acquired by Swiss National Bank - MarketBeat
Capula Management Ltd Purchases New Stake in Qiagen N.V. $QGEN - MarketBeat
Qiagen stock steadies as latest results highlight margin resilience and cash flow strength - Ad-hoc-news.de
Qiagen stock trades steadily as investors weigh recent earnings and molecular diagnostics growth - Ad-hoc-news.de
Qiagen stock holds steady as 2025 revenue and profit metrics frame the setup - Ad-hoc-news.de
Hsbc Holdings PLC Invests $12.92 Million in Qiagen N.V. $QGEN - MarketBeat
Qiagen stock steadies as investors weigh recent earnings and molecular diagnostics growth - Ad-hoc-news.de
PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG - TradingView
Release according to Article 40, Section 1 of the WpHG - TradingView
KKR (KKR) Launches Allyntra While Chasing DStelecom And Qiagen - Yahoo Finance
Qiagen stock trades steady as diagnostics revenue grows and margin focus intensifies - Ad-hoc-news.de
Qiagen stock trades steady as diagnostics demand supports earnings momentum - Ad-hoc-news.de
Qiagen stock trades steady as diagnostics demand supports recent earnings - Ad-hoc-news.de
Qiagen stock holds firm as diagnostics demand supports revenue growth - Ad-hoc-news.de
Qiagen stock trades steady as recent results highlight margin resilience - Ad-hoc-news.de
Qiagen stock rises on recent results and market data - Ad-hoc-news.de
Baader Bank Aktiengesellschaft Buys New Stake in Qiagen N.V. $QGEN - MarketBeat
Qiagen stock trades steadily as diagnostics demand supports earnings and cash flow - Ad-hoc-news.de
Qiagen stock trades steadily as recent earnings and margin trends shape investor focus - Ad-hoc-news.de
Qiagen stock trades steady as investors weigh recent earnings and diagnostics demand - Ad-hoc-news.de
Qiagen N.V. (QGEN) Stock Analysis: Evaluating The 7.09% Upside Potential For Investors - DirectorsTalk Interviews
DekaBank Deutsche Girozentrale Takes $10.81 Million Position in Qiagen N.V. $QGEN - MarketBeat
Qiagen stock holds as investors await fresh numbers - Ad-hoc-news.de
Qiagen stock trades steady as latest quarterly numbers highlight margin resilience - Ad-hoc-news.de
William Blair Initiates Qiagen NV(QGEN.US) With Hold Rating - Moomoo
Qiagen stock trades steadily as recent earnings and guidance frame valuation - ad-hoc-news.de
Qiagen stock steadies as investors weigh Q2 2025 earnings and diagnostics demand - ad-hoc-news.de
Qiagen stock rises on 2025 results and 2026 guidance - ad-hoc-news.de
Qiagen stock trades steady as diagnostics demand supports earnings and cash flow - Ad-hoc-news.de
BlackRock Builds Significant Stake in Qiagen, Boosting Institutional Presence - The Globe and Mail
Citigroup Discloses 2.85% Stake in QIAGEN via AFM Filing - The Globe and Mail
Citigroup Reports 3.09% Indirect Stake in Qiagen via AFM Filing - The Globe and Mail
Goldman Sachs discloses 3.5% voting interest in Qiagen - The Globe and Mail
Qiagen stock holds ground as investors look to next earnings after steady 2024 revenue - ad-hoc-news.de
Allspring Global Investments Holdings LLC Has $100.21 Million Position in Qiagen N.V. $QGEN - MarketBeat
Qiagen stock holds near recent levels as earnings metrics guide the story - ad-hoc-news.de
Qiagen stock holds steady as 2026 guidance and margins stay central - ad-hoc-news.de
Qiagen (QGEN) Investor presentation Summary - Quartr
Qiagen stock trades steady as Q1 2026 growth and margin resilience underpin outlook - ad-hoc-news.de
Qiagen stock trades steady as investors weigh Q1 2024 growth and margin trends - ad-hoc-news.de
Cancer Biomarkers Market to Reach US$ 54.48 Billion by 2032 as Precision Oncology and Multi-Omics Adoption Accelerate - GlobeNewswire Inc.
Barings LLC Sells 77,747 Shares of Qiagen N.V. $QGEN - MarketBeat
Qiagen stock trades steady as investors weigh recent earnings and molecular diagnostics demand - ad-hoc-news.de
Qiagen stock reflects steady diagnostics demand as earnings and cash flow support investment cycle - ad-hoc-news.de
QIAGEN Highlights Molecular Testing Solutions Supporting Response to Growing U.S. Cyclospora Outbreak - BioSpace
Qiagen highlights testing tools amid U.S. cyclosporiasis outbreak - Investing.com UK
Qiagen highlights testing tools amid U.S. cyclosporiasis outbreak By Investing.com - Investing.com South Africa
Qiagen Highlights Molecular Testing Solutions Supporting Response to Growing U.S. Cyclospora Outbreak - marketscreener.com
Qiagen stock holds steady as diagnostics demand supports the long-term story - Ad Hoc News
QIAGEN N.V. to release Q2 2026 results on August 5 - scanx.trade
Finanzdaten der Qiagen Nv-Aktie (QGEN)
Umsatz
Nettogewinn
Free Cashflow
ENV
8.61%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):